Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy (NCT05472350) | Clinical Trial Compass
UnknownNot Applicable
Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy
128 participantsStarted 2022-08-01
Plain-language summary
Cough after lobectomy is common. The prevention and treatment of cough after lobectomy is not standardized. Breztri Aerosphere is often used to relieve cough. Therefore, we conduct a single center placebo-controlled study to evaluate the efficacy and safety of perioperative use of Breztri Aerosphere in relieving cough after lobectomy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subjects voluntarily participate in this research and abide by the research regulations, understand and comply with and cooperate with the corresponding inspections, comply with the follow-up plan, and voluntarily sign the written informed consent.
✓. Outpatients, 18 years old ≤ age ≤ 70 years old, preoperative examination of cardiopulmonary function can tolerate surgery.
✓. Patients planning to undergo lobectomy.
✓. No obvious cough before surgery.
Exclusion criteria
✕. Participated in other interventional clinical trials 90 days before enrollment
✕. Pregnant and lactating women (budigrafo is not recommended during pregnancy and lactation)
✕. Patients with obvious cough before surgery (which affects the evaluation of drug effect)
✕. History of alcohol or narcotic drug abuse, or a history of mental illness, confrontational personality, bad motivation, paranoia, or other emotional or intellectual problems that may affect the informed validity of participation in this study